Navigation Links
The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Date:9/1/2010

COLD SPRING HARBOR, N.Y., Sept. 1 /PRNewswire/ -- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available online now at ASCOPost.com and appear in the September issue of the publication.

"It is important that the breast cancer community rest assured that ODAC is an independent, unbiased panel of experts in oncology whose mission is to provide their best objective scientific and clinical recommendations to the FDA for drug approval," said ODAC Chair, Wyndham Wilson, MD, PhD. Dr. Wilson is Chief of the Lymphoid Therapeutics Section of the Center for Cancer Research, National Cancer Institute.

Bevacizumab is currently approved in combination with paclitaxel for the first-line treatment of advanced HER2-negative breast cancer, based on encouraging results of the E2100 trial (N Engl J Med 357:2666-2676, 2007). The FDA provisionally granted accelerated approval but requested confirmatory data from the manufacturer, Genentech. In November 2009, Genentech supplied the results of the AVADO (J Clin Oncol 28:3239-3247, 2010) and RIBBON-1 trials (J Clin Oncol 27(abstract 1005), 2009). On July 20, 2010, ODAC recommended against conversion to full approval.

Joanne Mortimer, MD, a member of ODAC, who voted to approve bevacizumab in advanced breast cancer in December 2007 based on the E2100 study, said, "The additional data from AVADO and RIBBON-1 supported an increased response rate, but also confirmed the increased toxicity and lack of survival advantage with bevacizumab. Like the majority of panel [ODAC] members, I could not recommend approval." Dr. Mortimer is Director of the Women's Cancers' Program and Professor of Medical Oncolo
'/>"/>

SOURCE Harborside Press
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
3. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
4. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
5. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
6. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
7. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
8. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
9. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 On ... EcoLuxe Lounge in the Stardust Penthouse on the ... Durkin, Los Angeles’ leading sustainable product TV and ... this unforgettable day-long event, which featured some of ... ecologically sound products and services. , “We were ...
Breaking Medicine News(10 mins):Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2
... not all , WEDNESDAY, Oct. 17 (HealthDay News) -- There,s ... , That,s the conclusion of Israeli researchers who reviewed three ... to sham insoles or no treatment for back pain prevention. ... 256 people that focused on the use of insoles for ...
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... presentations at the AACR-NCI-EORTC International,Conference from Oct. 22-26 ... The poster presentations will focus on data concerning ...
... is Now Supported to Help Advance Research-, ... within the biomedical market for its innovative genomic ... Release 1.3,of SLIM Search. The SLIM Search genomic ... biomedical research and development.,Version 1.3 includes the following ...
... 17 /Xinhua-PRNewswire/ -- Mindray Medical,International Limited (NYSE: MR ... in China, today announced that it will report,its third ... on,November 1, 2007. Mindray,s management will hold an earnings ... Eastern Time (8:00 AM on November,2, 2007 Beijing/Hong Kong ...
... completing its review of safety,and efficacy data currently ... recommended that the pivotal Phase 3 clinical,trial FAME(TM) ... the current protocol, without change. The trial is ... of diabetic macular edema (DME). FAME is ...
... Oct. 17 Mirixa Corporation, a leading,developer ... facilitate,pharmacist-based patient care services, today announced the ... customized for each,participating pharmacy. RxFYI is free ... patient loyalty and generate revenue. "Patients ...
Cached Medicine News:Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Release 1.3 of SLIM Search Now Available 2Health News:Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue 2
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: